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1. Introduction
Targeting of nanocarriers in the human 
bloodstream to specific cell types is 
a major challenge for modern drug 
delivery.[1] Dendritic cells (DCs) are the 
most effective antigen-presenting cells and 
occupy a pivotal role in initiating T-cell-
mediated immunity.[2,3] As guardians of 
the immune system, they are specialized 
for the recognition and uptake of patho-
gens. Receptor-mediated uptake of patho-
gens into immature DCs leads to their 
maturation and migration to lymphoid 
organs in which they activate T-cells. DCs 
process microbial antigens and present 
them to resting T-cells, thereby initiating 
adaptive immune responses. Recent strat-
egies in the development of therapeutic 
vaccines have focused on the ability to 
deliver antigens to DCs, which can then 
trigger the desired T-cell function.[4] The 
delivery of nanocarriers to DCs while pre-
venting unspecific cellular uptake by other 
cells remains a challenge.[5]
Here, we present the selective 
uptake of polymeric nanocarriers to 
mono cyte-derived DCs (moDCs) by noncovalently attached 
polyphosphoesters (PPE) carrying mannose targeting units. To 
date, the targeting ligands (e.g., an antibody or carbohydrate) 
had been covalently attached to the nanocarriers.[6b,7] Covalent 
attachment of the targeting moieties often requires consider-
able synthetic efforts and is additionally plagued by low degrees 
of functionalization and the chemistry needs to be designed for 
each nanocarrier system.[8,9] In contrast, a noncovalent attach-
ment of targeting groups by adsorption allows transforming 
basically any material into a targeting nanocarrier.[10] Mannose 
was chosen as a targeting ligand to enable cellular recognition 
by monocyte-derived dendritic cells.[11,12]
However, designing nanocarriers with specific cell targeting 
for in vivo application bears additional challenges.[13] Once the 
nanocarriers are introduced to the bloodstream, proteins rap-
idly cover their surface and critically alter their physicochemical 
properties.[14b] Several reports recognized that targeting ligands 
were completely buried by blood proteins and specific cellular 
interactions were prevented.[6a,15] In order to minimize the 
Dendritic cells (DCs) are part of the immune system and can internalize 
pathogens by carbohydrate receptors. The uptake induces maturation 
and migration of the DCs resulting in an adaptive immune response by 
presenting antigens to T-cells. Thus, targeted delivery to DCs is a powerful 
tool for immunotherapy. However, in blood, specific targeting is challenging 
as blood proteins adsorb to the nanocarriers and mask the targeting 
molecules. Additionally, covalent coupling of targeting groups to nanocarriers 
requires new chemistry for each nanocarrier, while a general strategy is 
missing. A general protocol by noncovalent adsorption of mannosylated 
polyphosphoesters (PPEs) on the nanocarriers’ surface resulting in specific 
uptake into DCs combined with low protein adsorption of PPEs is presented. 
PPEs with hydrophobic anchors and multiple mannose units are reported and 
adsorbed to different model nanocarriers. Their protein corona remain similar 
to pure stealth nanocarriers and prove only low uptake into nontargeted 
cells (monocytes). Due to the “stealth” properties of PPEs, a high specific 
uptake into DCs is achieved after incubation in human blood plasma, 
proving an efficient combination of “stealth” and targeting after simple 
adsorption of the PPEs. This strategy can transform any nanocarrier into 
DC-targeting by noncovalent adsorption of PPEs and will aid in developing 
novel immunotherapies.
© 2019 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, 
Weinheim. This is an open access article under the terms of the Creative 
Commons Attribution License, which permits use, distribution and repro-
duction in any medium, provided the original work is properly cited.
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protein adsorption, we used polyphosphoesters to coat the nano-
carriers’ surface. PPEs are currently discussed as promising 
materials in biomedical applications,[16] as they have a versatile 
chemical structure,[17] are biodegradable, and proved to sup-
press unspecific cellular uptake (of PPEylated nanocarriers).[18] 
The PPE platform allowed us to prepare amphiphilic and 
manno sylated PPEs that were adsorbed on the surface of dif-
ferent nanocarriers. We were able to prove that the remaining 
protein corona on the PPEylated nanocarriers did not reduce 
the targeting ability of the mannose-functionalized nano-
carriers. Additionally, we carried out a detailed proteomic 
investigation to identify the distinct protein corona pattern 
underlining the combination of stealth properties together with 
specific targeting. This strategy proves the efficient combination 
of stealth and targeting properties that can be installed into dif-
ferent nanocarriers via coating with polyfunctional PPEs.
2. Results and Discussion
The mannosylated amphiphilic PPEs were designed to consist 
of a stearyl alcohol as the hydrophobic anchor and a hydrophilic 
PPE segment that was functionalized with several mannose 
units. The amphiphiles were prepared by the organocatalyzed 
ring-opening polymerization (ROP)[18b] of two different cyclic 
phosphoester monomers, that is, 2-methoxy-1,3,2-dioxaphos-
pholane 2-oxide (MEP)[19] and the side-chain functional 
2-((2-oxido-1,3,2-dioxaphospholan-2-yl)oxy)ethyl methacrylate 
(OPEMA).[20] PMEP was chosen as a hydrophilic PPE, while 
P(EPEMA) was chosen to attach thiol-modified mannose to 
the pendant methacrylates by a quantitative nucleophilic addi-
tion. Three different PPE amphiphiles with different amounts 
of reactive groups were prepared: Phos-S(1) was based on 
PMEP only, Phos-S(2) was a block copolymer (with 19 meth-
acrylate units), and Phos-S(3) was a homopolymer of OPEMA 
(with 37 methacrylate units, Figure 1). The P(EPEMA) units 
are water-insoluble intermediates, but after mannosylation the 
PPEs were water-soluble amphiphiles with surface tensions 
of 47.34 ± 0.07 mN for Phos-S(2)-Man and 51.21 ± 0.03 mN for 
Phos-S(3)-Man (camphiphile = 1 g L−1).
In all cases, stearyl alcohol was used as the initiator and the 
polymerization was catalyzed by 1,8-diazabicyclo[5.4.0]undec-
7-ene/thiourea (DBU/TU) as previously reported for other cyclic 
phospholanes.[21] The respective NMR spectra and size-exclusion 
chromatography (SEC) analyses are found in Figures S1–S22 
(Supporting Information). The monomer to initiator feed ratio 
allowed the adjustment of the number of functional groups in 
the PPE amphiphiles. All polymers exhibited moderate molar 
mass dispersities 1.2 < Ð < 1.5 and molar masses between 
5200 and 9000 g mol−1 (Table S1, Supporting Information). 
Phos-S(2) and Phos-S(3) were reacted with mercaptopropyl-α-d-
mannopyranoside (2), resulting in the mannosylated amphiphiles 
Phos-S(2)-Man (Mn(NMR) = 12 300 gmol−1) and Phos-S(3)-Man 
(Mn(NMR) = 18 400 gmol−1), carrying 19 or 37 mannose 
moieties, respectively (Table S2, Supporting Information).
To study the efficiency of these targeting amphiphiles for 
the receptor-mediated uptake into monocyte-dervived den-
dritic cells (moDCs), two different model nanocarriers (NCs) 
Adv. Sci. 2019, 1901199
Figure 1. Synthesis of polyphosphoester amphiphiles by ROP of cyclic phosphoester monomers and subsequent mannosylation by thiol–Michael 
addition. a) Preparation of Phos-S(1) without mannose moieties (for stealth behavior). b) Synthesis of block copolymer Phos-S(2) and subsequent 
mannosylation leading to Phos-S(2)-Man. c) Synthesis of Phos-S(3) by ROP of OPEMA and subsequent mannosylation by thiol–Michael addition 
leading to Phos-S(3)-Man.
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were prepared by free-radical miniemulsion polymerization of 
styrene or methyl methacrylate. The model nanocarriers had 
diameters of 101 ± 12 nm for polystyrene (PS) and 114 ± 15 nm 
for poly(methyl methacrylate) (PMMA, Table S3, Figures S23 
and S24, Supporting Information). The PPE-amphiphiles were 
subsequently adsorbed to the surface of the PS or PMMA nano-
carriers. The dispersions were characterized by dynamic light 
scattering (DLS) after the coating process proving that there was 
no aggregation in water (Figure 2). To underline the colloidal 
stability in human blood plasma, DLS of all PPE-coated NCs 
was conducted after incubation with blood plasma. There was 
no significant size increase before and after incubation with 
plasma (Figure S25, Supporting Information). Additionally, 
there were no cytotoxic effects for PPE-coated NCs (Figure S26, 
Supporting Information).
In order to evaluate whether the coating of NCs with man-
nose-functionalized PPE amphiphiles allows receptor-mediated 
cellular uptake, flow cytometry analysis toward moDCs was con-
ducted (Figure 3a,b). Flow cytometry analysis and confocal laser 
microscopy images (Figure 3e,f and Figure S27, Supporting 
Information) confirmed that both NCs coated with Phos-S(1) 
(no mannose) exhibit a low binding affinity toward moDCs 
indicating the stealth properties of a PPE-modified nanocarrier. 
In contrast, for both PS and PMMA nanocarriers, coated with 
mannose-functionalized PPEs (Phos-S(2)-Man or Phos-S(3)-
Man), we proved a significant increase in their cellular uptake 
into DCs (Figure 3c,d). This increased cellular uptake of the 
nanocarriers is already a good indication that the noncova-
lent adsorption of mannosylated PPEs on the NCs led to an 
increased receptor-mediated uptake into the DCs. Additionally, 
we observed that NCs coated with Phos-S(3)-Man displayed a 
significantly higher cellular internalization compared to NCs 
coated with Phos-S(2)-Man. As the mannose–lectin interaction 
is a cooperative effect, this difference in cellular uptake might 
be directly linked to the higher amount of mannose units in 
Phos-S(3)-Man compared to Phos-S(2)-Man. To prove this 
hypothesis and to investigate the accessibility of the mannose 
unit on the nanocarriers´ surface, a lectin binding assay was 
performed. Therefore, NCs were incubated with a fluorescently 
labeled lectin, which specially recognizes mannose units. If the 
lectin binds to the mannose unit on the nanocarriers’ surface, 
this newly formed complex can be detected via flow cytometry. 
Here, a significantly higher amount of mannose on the surface 
of Phos-S(3)-Man-coated NCs compared to Phos-S(2)-Man was 
detected (Figure S28, Supporting Information).
In order to verify a CD206/CD209 receptor-mediated uptake 
of the mannose-modified NCs, blocking experiments were 
performed (Figure 3c,d). Cells were pretreated with mannan, 
which strongly binds to the mannose receptor and blocks it for 
further docking of the NCs. Blocking with mannan proved a 
strong reduction of the internalization of all mannose-modified 
NCs, as the mannose receptor could not further recognize the 
mannose units on the PPEylated NCs (p < 0.001***). These 
experiments clearly prove that the prepared PPE increased a 
receptor-mediated uptake of nanocarriers into DCs. As a com-
plementary approach, the mannose receptor was blocked with 
soluble antibodies (Figure S29, Supporting Information). If 
cells were treated with antibodies prior to uptake analysis, cel-
lular interactions of NCs coated with mannose PPE amphiph-
iles were also reduced, proving the receptor-mediated uptake of 
mannose-PPEylated NCs.
The previous cell experiments confirmed the targeting under 
artificial conditions in cell culture medium, but in the absence 
blood plasma proteins. The loss of specific targeting after blood 
incubation had been reported as plasma proteins tend to bury 
the targeting groups.[6a,13] Also in our case, after incubation into 
human blood plasma, the cellular uptake of the nanocarriers 
was influenced by the protein corona: Flow cytometry experi-
ments indicated that PS nanocarriers, which were coated with 
both mannosylated amphiphiles, exhibited a lower cell inter-
nalization after the protein corona formation compared to the 
protein-free scenario (Figure 4b). This effect was more pro-
nounced for Phos-S(3)-Man compared to Phos-S(2)-Man, prob-
ably due to the overall stronger cell uptake in the former case 
(p < 0.001***). However, a significantly higher amount of the 
mannosylated NCs was still selectively taken up into the DCs as 
compared to Phos-S(1)-coated NCs. The low protein adsorption 
onto PPEylated surfaces still guaranteed access to the mannose 
units and resulted in a cellular uptake into the DCs. As PPEs 
were recently identified by our group as potential stealth poly-
mers that reduce unspecific cell uptake by selected adsorption 
of lipoproteins,[22] we conducted a detailed proteomic analysis 
of the mannose-modified PPEylated NCs. All identified pro-
teins were classified into eight different classes depending on 
their biological function (Figure 4c,d). In general, the amount 
of adsorbed protein and the overall corona composition were 
very similar for the mannosylated and non-mannosylated NCs 
(Figure S30, Supporting Information). The corona of Phos-
S(3)-coated PS NCs was enriched with lipoproteins (19%) com-
pared to NCs coated with Phos-S(1) (9%) or Phos-S(2) (13%) 
(Figure 3d, and Figures S31–S33, Supporting Information). 
In previous studies, we found that lipoproteins, in particular 
clusterin, interacted with PEGylated and PPEylated NCs and 
reduced the cellular interactions with macrophages.[22a] Their 
presence in the corona explains the reduced uptake and indi-
cates that corona proteins can shield the targeting ligand, but 
do not suppress the interaction with the mannose receptor. 
Interestingly, the internalization of the PMMA NCs seemed 
Adv. Sci. 2019, 1901199
Figure 2. Characteristics of polystyrene and poly(methyl methacrylate) 
nanocarriers coated with PPE amphiphiles.
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to be relatively unaltered in the presence of blood proteins 
(Figure 4a). We even detected an enhanced cellular uptake 
(p < 0.001***) for PMMA NCs coated with Phos-S(2)-Man after 
corona formation. This effect can be explained by the distinct 
corona composition. We detected a higher amount of immu-
noglobulins (15%) on the surface of Phos-S(2)-Man-coated NCs 
compared to Phos-S(1)-Man (6%) or Phos-S(3)-Man ones (9%). 
Immunoglobulins are referred to the class of opsonins, which 
are known to enhance interaction with immune cells.[23] There-
fore, the interaction of Phos-S(2)-Man-coated PMMA NCs and 
moDCs could be favored.
The specificity of the mannosylated-NCs for DCs was fur-
ther underlined by incubation with monocytes. Monocytes 
are one type of precursor cells of DCs and are the first cells, 
which recognize invading pathogens. However, they only 
express low levels of the mannose receptor (CD206/CD209, 
Adv. Sci. 2019, 1901199
Figure 3. Interactions of PPEylated nanocarriers with dendritic cells. a,b) Flow cytometry analysis: untreated cells (black), Phos-S(1) (blue), Phos-S(2)-
Man (orange), and Phos-S(3)-Man (red)-coated NCs (PS = polystyrene, PMMA = poly(methyl methacrylate)). c,d) Dendritic cells were incubated with 
NCs (150 µg mL−1) for 2 h, 37 °C. Cellular uptake was quantified by flow cytometry and values are expressed % positive cells ± SD from triplicates 
(gray bars). For blocking experiments, cells were pretreated with mannan (3 mg mL−1) for 30 min, 4 °C (red bars). e,f) Representative CLSM of dendritic 
cells incubated with PPE-coated NCs (150 µg mL−1) for 2 h, 37 °C. The cell membrane was stained with CellMask Orange and is pseudo-colored in red 
whereas the NCs were pseudo-colored in green. Scale bar: 20 µm.
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Figure S34, Supporting Information). As expected, the non-
mannosylated PPEylated NCs were also not taken up by the 
monocytes. More importantly, the mannosylated NCs only 
exhibited a very low internalization into monocytes, which 
further underlines their specific interaction with the mannose 
receptor of dendritic cells even in the presence of the protein 
corona (PMMA: Figure 5b and PS: Figure S35, Supporting 
Information).
Finally, we investigated the influence of the mannose den-
sity on the targeting efficiency. Therefore, PMMA nanocarriers 
were coated with different amounts of Phos-S(3). Here, we 
found that there was no linear correlation between the man-
nose amount and the cell uptake behavior (Figure 5c). Upon a 
certain threshold, the cellular uptake significantly increased. As 
described, the mannose receptor (CD206/CD209) specifically 
recognized multivalent mannose units meaning that the NCs 
need to be coated with a high mannose density.[24] In the case 
of Phos-S(2), the cell interaction was lower compared to Phos-
S(3) (Figures 4 and 5). This goes along with a slightly lower 
mannose density. As initially investigated via the lectin binding 
assay, there was also a higher accessibility of the mannose 
for Phos-S(3)-coated NCs compared to Phos-S(2)-coated NCs 
(Figure S28, Supporting Information).
3. Conclusion
The control of the protein adsorption from human blood 
plasma is crucial to establish specific cell targeting of nano-
carriers. Herein, we adsorbed amphiphilic and mannosylated 
polyphosphoesters on the surface of model polymeric nanocar-
riers. The combination of the stealth properties of the polyphos-
phoester with the additional possibility to attach targeting units 
to the pendant phosphoester proved an effective strategy to 
achieve the receptor-mediated uptake into dendritic cells of the 
immune system even after contact with human blood. Addi-
tionally, an overall low uptake in nontargeted cells (monocytes) 
was found. Therefore, the here presented approach allows 
the targeting of any nanocarrier into dendritic cells by simply 
adsorption of the mannosylated PPE-amphiphiles on their 
surface. This is a step toward understanding and controlling 
the behavior of functional drug delivery vehicles in blood.
Figure 4. a,b) Cell interactions of NCs after blood incubation: PPE-coated PS or PMMA NCs were exposed to human blood plasma and the 
cellular uptake (150 µg mL−1, 2 h) toward dendritic cells was quantified via flow cytometry. Values are expressed as mean ± SD from triplicates. 
c,d) Protein corona analysis from mass spectrometry based proteomics. All identified proteins were classified into eight different protein 
classes depending on their biological function. A full list of all detected proteins is summarized in a separate Excel Sheet (Table S4, Supporting 
Information).
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from the author.
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Figure 5. a) PPE amphiphiles adsorbed on polymer nanocarriers possess stealth and targeting properties. b) PMMA nanocarriers were exposed to 
human blood plasma and cellular uptake (150 µg mL−1, 2 h) toward dendritic cells (blue) or monocytes (red) was quantified via flow cytometry. Values 
are expressed as mean ± SD from triplicates. c) PMMA nanocarriers were incubated with different amounts of mannoslyated PPE-amphiphile. Cellular 
uptake toward moDCs (150 µg mL−1, 2 h) of Phos-S(3)-coated nanocarriers was analyzed via flow cytometry after plasma coating. Values are expressed 
as mean ± SD from duplicates.
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